@article{458263b719ef45e6be5107af2e8beabd,
title = "No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy",
abstract = "Background/Objectives: Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency is unknown. Design/Methods: Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) ≥1% at Day 15/Day 19 of induction or ≥0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender. Results: There was no difference in Day 15/19 (P = 1) or end of induction MRD (P = 0.76) nor in the number of RBC transfusions (P = 0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P = 0.78). Conclusion: We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.",
keywords = "daunorubicin, doxorubicin, glucose-6-phospate dehydrogenase, leukemia, pharmacogenetics",
author = "Robinson, {Katherine M.} and Wenjian Yang and Karol, {Seth E.} and Nancy Kornegay and Dennis Jay and Cheng Cheng and Choi, {John K.} and Dario Campana and Pui, {Ching Hon} and Brent Wood and Borowitz, {Michael J.} and Julie Gastier-Foster and Larsen, {Eric C.} and Naomi Winick and Carroll, {William L.} and Loh, {Mignon L.} and Raetz, {Elizabeth A.} and Hunger, {Stephen P.} and Meenakshi Devidas and Mardis, {Elaine R.} and Fulton, {Robert S.} and Relling, {Mary V.} and Sima Jeha",
note = "Funding Information: National Institutes of Health, Grant/Award Numbers: CA114766, CA142665, CA180886, CA180899, CA21765, CA36401, CA98413, CA98543, GM115279; St. Baldrick's Foundation; ALSAC Funding Information: This study was supported by NIH grants CA 21765, CA 142665, CA 36401, P50 GM 115279, U10 CA98543 and U10 CA180886 (COG Chair's grants), U10 CA98413 and U10 CA180899 (COG Statistics and Data Center grants), and U24 CA114766 (COG Specimen Banking); St Baldrick's Foundation funding; and by ALSAC. MLL is the Benioff Chair of Children's Health and the Deborah and Arthur Ablin Endowed Chair for Pediatric Molecular Oncology at Benioff Children's Hospital. EAR is a KiDS of NYU Foundation Professor at NYU Langone Health. SPH is the Jeffrey E. Perelman Distinguished Chair in Pediatrics at The Children's Hospital of Philadelphia. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",
year = "2019",
month = jun,
doi = "10.1002/pbc.27681",
language = "English (US)",
volume = "66",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",
}